We have developed an RNA probe hybridization enzyme immunoassay for detection of human parvovirus B19 PCR-amplified DNA. The assay is easy to perform and increases assay sensitivity without the added inconvenience and risk of false-positive results associated with nested PCR.
Determination of acute infection with human parvovirus B19 can often be accomplished by detection of specific immunoglobulin M (IgM) antibodies (1, 8) . Because of the occasional occurrence of false-positive IgM results (4) and the potential for false-negative results for persons with immune deficiencies, accurate diagnosis often requires confirmation by detection of virus or viral DNA. PCR assay combined with gel electrophoresis and ethidium bromide fluorescence or Southern blot is currently the most sensitive method for detecting B19 DNA (7, 10, 17) . We and others have shown that a second amplification with nested primers provides added sensitivity essential for detection of B19 DNA in some clinical samples (5, 10, 14, 15, 20) . However, this second amplification is costly and time-consuming and increases the risk of false-positive results from contaminating DNA.
In this report, we describe a nonradioactive microtiter plate-based RNA probe hybridization enzyme immunoassay (RPEIA) for detection of B19 PCR-amplified DNA that takes advantage of the fact that oligomeric primers can be labeled with a variety of haptens without adversely affecting the efficiency of the amplification reaction (9, (11) (12) (13) . The sensitivity of the RPEIA was compared with those of ethidium bromide fluorescence for detection of the primary PCR product and of nested PCR, and its diagnostic value was determined with clinical samples.
Pooled Oligonucleotide primers specific to a conserved region of the NS1 gene coding for the B19 nonstructural protein were prepared (19) . Primers P1 and P6 were used for primary PCR amplification, yielding a 284-bp product; nested primers P2 and P5 were used to amplify an internal 102-bp product and to prepare the RNA probe. The primer sequences and the method of synthesis have been previously described (9) . For biotin labeling, dimethoxytrityl-biotin C6 phosphoramidite (Cambridge Research Biochemicals, Norwich, United Kingdom) was used during primer synthesis to incorporate a single biotin molecule at the 5' end of P1.
Our standard PCR and nested-PCR assays were performed as previously described (9) . For detection by RPEIA, biotinlabeled P1 was substituted for unlabeled P1 at an identical concentration (0.5 M). No differences in amplification efficiency between the biotin-labeled and unlabeled primers were noted. Positive B19 DNA controls containing 10 pg/ml (total B19 DNA, 100 fg) and 1 pg/ml (total B19 DNA, 10 fg) and negative water controls were included in each amplification reaction.
For preparation of the RNA probe, the TA Cloning System (Invitrogen Corp., San Diego, Calif.) kit was used to directly clone the 102-bp B19 nested PCR amplification product into plasmid vector pCR 1000 provided in the kit. The TA Cloning System takes advantage of the ability of Taq polymerase to add single deoxyadenosines to the 3' ends of all duplex molecules. Because the vector provided in the kit is supplied as a linear molecule with single 3' T overhangs at the insertion site, PCR products can be directly cloned immediately after amplification and their sequences can be transcribed from an available T7 polymerase promoter; subsequent modification of the version 1.0 vector used in this study has purportedly improved both the versatility and percent recovery expected with this procedure (lla). All reactions were carried out according to the manufacturer's instructions. Of 20 recombinant colonies recovered and screened by PCR with primers P2 and PS, two were positive for the 102-bp insert. Minipreparations of the plasmid DNA from these two colonies were prepared by the alkali lysis method of Sambrook et al. (18) a PCR and nested-PCR (nPCR) products detected by gel electrophoresis and ethidium bromide fluorescence (EBF) and the RPEIA. PCR-EBF results were quantitated as follows: no band, -; a band present, but no more intense than the 10-fg control, +; approximately the same intensity as the 100-fg control, ++; and of a greater intensity than the 100-fg control, + + +. The cutoff for a positive RPEIA was taken as the mean OD plus 5 standard deviations of the 10 B19 DNA-negative serum specimens (OD = 0.035). The be expected, given the specificity of the amplification reaction. Moreover, the added probe length likely increases the number of incorporated digoxigenin labels and therefore increases the potential specific activity of the probe.
Using this probe, we were able to devise an assay for detection of B19 PCR-amplified DNA that increased the sensitivity of our single-cycle PCR and eliminated the need for nested PCR, thereby reducing the risk of false-positive results associated with a second amplification. The RPEIA combines the advantages of incorporative labeling of the PCR product with biotin to facilitate capture of the product-probe hybrid with those of liquid-phase hybridization with the digoxigeninlabeled RNA probe for rapid and specific detection of the PCR product. We achieved at least a 10-fold increase in sensitivity over our standard PCR protocol for detection of B19 target DNA, giving us a level of detection of between 3 and 30 genome copies, equivalent to the sensitivity of our nested PCR assay (10) . The diagnostic value of this increased sensitivity was best illustrated in this study by two cases: (i) patient 14, for whom a serum specimen was unavailable and for whom diagnosis was accomplished by PCR amplification of bone marrow samples, and (ii) patient 18, for whom B19 DNA was detected in serum negative for specific IgM antibodies. Although repeat extractions of the clinical specimens gave similar results, the possibility of B19 DNA contamination could not be ruled out in these cases. Moreover, by adapting the RPEIA to a microtiter plate format, coupled with colorimetric detection, we were able to simplify the procedure and make it more compatible with our current EIA protocols for detection of B19-specific antigen and antibodies (1) .
